Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal

BACKGROUND: Immune checkpoint blockade (ICB) induces durable clinical responses in patients with various types of cancer. However, its limited clinical efficacy requires the development of better approaches. In addition to immune checkpoint molecules, tumor-infiltrating immunosuppressive cells inclu...

Descripción completa

Detalles Bibliográficos
Autores principales: Isoyama, Sho, Mori, Shigeyuki, Sugiyama, Daisuke, Kojima, Yasuhiro, Tada, Yasuko, Shitara, Kohei, Hinohara, Kunihiko, Dan, Shingo, Nishikawa, Hiroyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395371/
https://www.ncbi.nlm.nih.gov/pubmed/34446575
http://dx.doi.org/10.1136/jitc-2020-002279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8395371/
https://www.ncbi.nlm.nih.gov/pubmed/34446575
http://dx.doi.org/10.1136/jitc-2020-002279

Ejemplares similares